Abstract

Background: Pregnancy-induced hypertension (PIH) remains a leading cause of maternal and perinatal morbidity and mortality worldwide, particularly in low- and middle-income countries. Despite advances in obstetric care, preventive strategies with long-term safety and fetal compatibility remain limited. Ayurveda emphasizes preventive antenatal care (Garbhini Paricharya), wherein Rasayana therapy plays a pivotal role in maintaining maternal homeostasis and preventing disease manifestation. Objective: To critically review classical Ayurvedic concepts and contemporary scientific evidence regarding the role of Rasayana in the prevention of pregnancy-induced hypertension. Methods: A systematic review was conducted following PRISMA 2020 guidelines. Electronic databases including PubMed, Scopus, Web of Science, Google Scholar, and AYUSH Research Portal were searched from inception to December 2025. Classical Ayurvedic texts (Brihattrayi and major Nighantus) were reviewed for conceptual correlations. Clinical, experimental, and observational studies evaluating Rasayana drugs or formulations relevant to PIH prevention were included. Results: A total of 63 records were identified, of which 41 studies met inclusion criteria. Classical literature describes Rasayana as promotive of Ojas, vascular integrity, and Tridosha balance—pathophysiological domains relevant to PIH. Modern studies indicate that commonly used Rasayana agents such as Ashwagandha, Shatavari, Amalaki, and Guduchi exhibit antihypertensive, antioxidant, endothelial protective, and anti-inflammatory properties. However, robust pregnancy-specific randomized controlled trials are limited. Conclusion: Rasayana therapy demonstrates substantial theoretical and emerging scientific potential in the prevention of PIH. Integrative, well-designed clinical trials are warranted to establish safety, efficacy, and standardized antenatal protocols.